Type-2 diabetic nephropathy in Japan : from bench to bedside
著者
書誌事項
Type-2 diabetic nephropathy in Japan : from bench to bedside
(Contributions to nephrology, v. 134)
Karger, c2001
- タイトル別名
-
Type-two diabetic nephropathy in Japan : from bench to bedside
大学図書館所蔵 全1件
  青森
  岩手
  宮城
  秋田
  山形
  福島
  茨城
  栃木
  群馬
  埼玉
  千葉
  東京
  神奈川
  新潟
  富山
  石川
  福井
  山梨
  長野
  岐阜
  静岡
  愛知
  三重
  滋賀
  京都
  大阪
  兵庫
  奈良
  和歌山
  鳥取
  島根
  岡山
  広島
  山口
  徳島
  香川
  愛媛
  高知
  福岡
  佐賀
  長崎
  熊本
  大分
  宮崎
  鹿児島
  沖縄
  韓国
  中国
  タイ
  イギリス
  ドイツ
  スイス
  フランス
  ベルギー
  オランダ
  スウェーデン
  ノルウェー
  アメリカ
注記
Includes bibliographical references and indexes
内容説明・目次
内容説明
Type-2 diabetic nephropathy is one of the major long-term microvascular complications occurring in nearly 40% of diabetic patients in Japan. The purpose of this book is to review recent work on the genetic background, pathogenesis and treatment of this disorder and to provide the most up-to-date findings on these subjects in Japan. The pathogenesis of diabetic nephropathy includes both metabolic and / or hemodynamic factors, as well as renal hypertrophy. Hyperglycemia is necessary, but not sufficient, for its initiation and progression: The toxicity of persistent hyperglycemia results from glucose overutilization and multiple secondary effects. Moreover, diabetic nephropathy is generally considered to alter the chemical composition of the glomerular basement membrane and mesangium. At present, it is supposed that the increases in extracellular matrix accumulation due to TGF-beta activation might be related to the glomerular sclerosis in diabetic nephropathy. Although large numbers of candidate genes have been analyzed, those related to initiation and progression are still obscure in patients with type-2 diabetic nephropathy. Presenting clinical findings and issues related to laboratory analysis, this book will be of interest for nephrologists, diabetologists, pathologists, biochemists, general physicians and residents.
目次
- Basic findings: genetic background - patients, Makita, Y., Tomino, Y.
- animal models, Shike, T., Funabiki, K., Tomino, Y.
- mesangial cell dysfunction as a pathogenesis of diabetic nephropathy, Haneda, M., Koya, D., Kikkawa, R.
- advanced glycation end products and the pathogenesis of diabetic nephropathy, Yamagishi, S., Takeuchi, M., Makita, Z.
- carbonyl stress, Suzuki, D., Miyata, T., Kurokawa, K.
- role of macrophages in the pathogenesis of diabetic nephropathy, Shikata, K., Makino, H.
- lipid abnormality, Mune, M., Otani, H., Kimura, K.
- impairment of ECM production, Horikoshi, S., Kanamaru, Y., Funabiki, K., Tomino, Y.
- podocyte loss and progression of diabetic nephropathy, Shirato, I., Hishiki, T., Tomino, Y.
- efficacy of ACE inhibitor (captopril) on glomerular antioxidant enzyme activity and hypertension in diabetic hypertensive rats, Shou, I., Fukui, M., Tomino, Y.. Clinical findings and treatment: classification of Type-2 diabetic nephropathy in Japan, Tomino, Y.
- serum cystatin C, Tomino, Y.
- urinary type-IV collagen, Tomino, Y.
- urinary albumin fragments, Yagame, M., Sakai, H.
- renal biopsy findings and clinical course, Nishi, S., Ueno, M., Gejyo, F.
- blood glucose control, Uchino, H., Kawamori, R.
- blood pressure control in diabetic nephropathy, Katayama, S.
- dietary protein restriction and nutritional adequacy in diabetic nephropathy, Kanauchi, M.
- future strategy - gene therapy for diabetic nephropathy, Isaka, Y., Imai, E.. Summary: Tomino, Y.
「Nielsen BookData」 より